A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

ClinicalTrials.gov ID: NCT04978727

Public ClinicalTrials.gov record NCT04978727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Study identification

NCT ID: NCT04978727
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Children's Oncology Group; Network
Enrollment: 35 participants

Conditions and interventions

Conditions

Interventions

SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years Biological
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years Biological
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years Biological

Biological

Eligibility (public fields only)

Age range: 1 Year to 21 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2022
Primary completion: Apr 29, 2027
Completion: Feb 27, 2030
Last update posted: Apr 5, 2026

2022 – 2030

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Children's Hospital Los Angeles	Los Angeles	California	90026	—
Lucile Packard Children's Hospital at Stanford University Medical Center	Palo Alto	California	94304	—
Children's Hospital Colorado	Aurora	Colorado	80045	—
Children's National	Washington D.C.	District of Columbia	20010	—
University of Florida	Gainesville	Florida	32608	—
Children's Healthcare of Atlanta	Atlanta	Georgia	30322	—
Ann and Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	60611	—
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14263	—
Memorial Sloan Kettering	New York	New York	10065	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
Nationwide Children's Hospital	Columbus	Ohio	43205	—
UPMC Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania	15224	—
Texas Children's Hospital	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04978727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 5, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04978727 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →